Nature Communications Archives
VUMC scientists discover key step to kidney fibrosis
Nov. 21, 2023—Researchers at Vanderbilt University Medical Center for the first time have shown that activation of the epidermal growth factor receptor (EGFR) is essential for the development of kidney fibrosis, tissue scarring following injury that can lead to kidney failure.
Study details RNA editing in virus-infected cancer cells
Apr. 20, 2023—Vanderbilt researchers detail the landscape of RNA editing — a form of RNA modification — in primary effusion lymphoma cells during Kaposi’s sarcoma-associated herpesvirus infection and identify an edited viral microRNA that is critical for infection.
New approach outperforms existing cancer susceptibility models
Jan. 5, 2023—A new approach for conducting gene-based analyses for cancer susceptibility created at Vanderbilt outperforms existing models.
Study reveals pathways for aggressive prostate cancer subtype
Oct. 27, 2022—Research from Vanderbilt-Ingram Cancer Center has revealed new information about the molecular pathways of cribriform prostate cancer.
Study suggests new mechanism for lipid transporter
Sep. 15, 2022—A new model suggests that a protein involved in the generation of high-density lipoprotein (HDL) works differently than previously thought.
Inflammatory driver of obesity
Aug. 25, 2022—Blocking the EGF receptor signaling pathway in immune system macrophages represents a new target for improving insulin resistance in people with obesity.
Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine
Jul. 20, 2022—In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.
Study advances understanding of bacterial bioterrorism agent
Apr. 7, 2022—Vanderbilt researchers have identified a critical regulatory factor in the bacterium that causes the disease anthrax and has been used as a biological weapon.
New method enhances efforts to identify drug repurposing targets
Jan. 20, 2022—Researchers at Vanderbilt University Medical Center have developed a new method for identifying drugs for the repurposing trials that can lead to new indications for drugs already in use.
‘Multi-omics’ reveals treatment option for breast cancer subtype
Nov. 18, 2021— by Bill Snyder In a multidisciplinary collaboration, researchers at Vanderbilt University Medical Center and the University of Miami Miller School of Medicine have identified a subtype of triple-negative breast cancer (TNBC) that appears to be able to escape detection by the immune system and evade immunotherapy. Their report, published Nov. 1 in the journal...
Study shows how a protein coding gene confers breast cancer susceptibility during DNA transcription
Sep. 30, 2021—Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.
Discovery offers insight for development of cancer therapies targeting mutant p53
Sep. 2, 2021—Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.
